TMO Thermo Fisher Scientific Inc.

Price (delayed)

$365.89

Market cap

$144.51B

P/E Ratio

39.81

Dividend/share

$0.82

EPS

$9.19

Enterprise value

$161.5B

Business Summary

Sector: Healthcare
Industry: Diagnostics & Research
Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Highlights

Thermo Fisher Scientific Inc's quick ratio has soared by 53% YoY and by 25% from the previous quarter
The company's equity fell by 3.8% QoQ but it rose by 3.1% YoY
The stock's price to earnings (P/E) is 26% more than its 5-year quarterly average of 31.5 and 22% more than its last 4 quarters average of 32.6
The debt has increased by 13% QoQ and by 10% YoY

Key stats

Shares outstanding
394.95M
Market cap
$144.51B
Enterprise value
$161.5B
EBIT
$4.88B
EBITDA
$7.18B
Price to earnings (P/E)
39.81
Price to book (P/B)
5.11
Price to sales (P/S)
5.66
EV/EBIT
33.07
EV/EBITDA
22.5
Net debt/EBITDA
2.37
EV/Sales
6.3
EBITDA margin
28%
Gross margin
44.3%
Net margin
14.3%
Operating margin
17.9%
Return on assets
6.3%
Return on equity
12.6%
Return on invested capital
17.4%
Return on capital employed
9.2%
Return on sales
19%
Debt to equity
0.7
Free cash flow
$3.74B
Free cash flow per share
$9.41
Book value per share
$71.61
Revenue per share
$64.6
TBVPS
$49.2
Current ratio
2.32
Quick ratio
1.36
Working capital
$7.24B
Dividend yield
0.22%
DPS
$0.82
Payout ratio
8.9%

TMO stock price

Financial performance

The operating income has grown by 17% YoY
Thermo Fisher Scientific Inc's net income has increased by 16% YoY
Thermo Fisher Scientific Inc's operating margin has increased by 13% YoY
The net margin has increased by 11% YoY

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
39.81
The stock's price to earnings (P/E) is 26% more than its 5-year quarterly average of 31.5 and 22% more than its last 4 quarters average of 32.6
TMO's EPS is up by 16% year-on-year
Price to book (P/B)
Current price to book (P/B):
5.11
The P/B is 60% above the 5-year quarterly average of 3.2 and 25% above the last 4 quarters average of 4.1
The company's equity fell by 3.8% QoQ but it rose by 3.1% YoY
Price to sales (P/S)
Current price to sales (P/S):
5.66
The P/S is 49% above the 5-year quarterly average of 3.8 and 20% above the last 4 quarters average of 4.7
Thermo Fisher Scientific Inc's revenue has increased by 4.1% YoY

Efficiency

TMO's ROA is up by 11% YoY but it is down by 3.1% from the previous quarter
TMO's return on invested capital is up by 9% year-on-year
TMO's ROS is up by 9% year-on-year and by 2.2% since the previous quarter
The ROE has grown by 8% YoY

Dividends

DPS
$0.82
Dividend yield
0.22%
Payout ratio
8.9%

Recent dividends

Financial health

Assets vs liabilities
The total assets is 95% greater than the total liabilities
Thermo Fisher Scientific Inc's quick ratio has soared by 53% YoY and by 25% from the previous quarter
The current ratio has increased by 37% year-on-year and by 21% since the previous quarter
Debt vs equity
The debt is 30% lower than the equity
Thermo Fisher Scientific Inc's debt to equity has increased by 17% QoQ and by 6% YoY
The debt has increased by 13% QoQ and by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.